Preoperative Carfilzomib and Lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model.

Sensitized patients are difficult to transplant due to pre-formed anti-donor immunity. We have previously reported successful desensitization using carfilzomib and belatacept in a non-human primate (NHP) model. Here we evaluated selective blockade of the co-stimulatory signal (CD28-B7) with Lulizumab, which preserves the co-inhibitory signal (CTLA4-B7). Five maximally MHC-mismatched pairs of NHPs were sensitized to each other with two sequential skin transplants. Individuals from each pair were randomized to either desensitization with once-weekly Carfilzomib (27mg/m2 IV) and Lulizumab (12.5mg/kg SC) over four weeks, or no desensitization (Control).

Source: Kidney International - September 4, 2020 Category: Urology & Nephrology Authors: Paul M. Schroder, Robin Schmitz, Zachary W. Fitch, Brian Ezekian, Janghoon Yoon, Ashley Y. Choi, Miriam Manook, Andrew Barbas, Frank Leopardi, Mingqing Song, Alton B. Farris, Bradley Collins, Jean Kwun, Stuart J. Knechtle Tags: basic research Source Type: research